Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INT-747 plus ursodeoxycholic acid in primary biliary cirrhosis
NL-OMON33908Phase 2Active, not recruiting
- Sponsor
- Intercept Pharmaceuticals
- Start
- Apr 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of obeticholic acid and ursodeoxycholic acid in primary biliary cholangitis (PBC) (4 arms), sponsored by Intercept Pharmaceuticals. Primary endpoints: Change in serum alkaline phosphatase and Safety. Started Apr 2009; status: active, not recruiting.
02
Drugs
obeticholic acidursodeoxycholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NL-OMON33908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33908.